Pharm
Baricitinib
search
Baricitinib
, Olumiant
See Also
Janus Kinase Inhibitor
Indications
Rheumatoid Arthritis
Refractory to non-biologic
DMARD
Alopecia Areata
Severe
Alopecia Areata
in adults
Dosing
Rheumatoid Arthritis
(refractory to non-biologic
DMARD
)
Take 2 mg orally once daily
Alopecia Areata
Start 2 mg orally once daily
May advance to 4 mg orally once daily if lack of response to 2 mg/day
Efficacy
Alopecia Areata
Hair
regrowth starts 8 to 12 weeks after starting Baricitinib and continues up through 36 weeks
Best efficacy is with 4 mg dose
Up to a third of patients will achieve <20% scalp baldness
Adverse Effects
See
Janus Kinase Inhibitor
Common (5% of patients)
Upper Respiratory Infection
s
Urinary Tract Infection
Hyperlipidemia
Headache
s
Nasopharyngitis
Acne
Increased
Serum Creatinine
kinase levels
Serious
Class effects include serious infections, opportunistic infections (e.g. Tb reactivation,
Shingles
reactivation), malignancy
See
Janus Kinase Inhibitor
Major cardiovascular events (0.5%)
Malignancy including non-melanoma
Skin Cancer
(0.4%)
Safety
Avoid in pregnancy (Unknown safety)
Avoid in
Lactation
Wait at least 4 days after last dose to begin
Breast Feeding
Resources
Baricitinib (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf
References
Pheasant (2023) Am Fam Physician 108(5): 513-4 [PubMed]
Type your search phrase here